Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19

120 First-in-Class Programs Mean Glioblastoma Market Set for Strong Innovation

By Adam Bradbury, MSc, Associate Analyst, GBI Research | August 31, 2016

Glioblastoma, a particularly aggressive form of brain tumor, has a promising treatment pipeline, with 120 first-in-class programs acting on 86 first-in-class molecular targets, according to business intelligence provider GBI Research.

The company’s latest report states that the glioblastoma therapy pipeline, which includes 512 products active across all stages of development, is moderately sized but highly innovative. Potential factors driving the pipeline include vast unmet need, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market landscape, and a recently improved understanding of the disease pathophysiology, facilitating the development of novel compounds.

Pipeline innovation has far-reaching strategic implications for all market participants as, despite the high attrition rate in glioblastoma, it is highly likely that many of the numerous first-in-class products, a number of which are supported by promising preclinical data, will reach the market over the coming decade, potentially transforming the clinical and commercial landscape.

For players in the market, the case for investment in innovative products has not weakened as a result of the challenging commercial environments in developed markets and, increasingly, developed nations. On the contrary, despite higher stakes and greater risks, the return on investment for innovative products reaching the market remains attractive and could increase in significance in years to come.

There are many signaling pathways and cellular processes in glioblastoma that remain untargeted by the limited number of associated marketed products. While growth factor signaling, such as by vascular endothelial growth factor, is inhibited in current glioblastoma treatments, evidence is mounting for the importance of other parallel mechanisms, such as cancer stem cell growth, and extracellular matrix remodeling.

In terms of the glioblastoma deals landscape, activity is moderate and the mean value for co-development deals is below the industry average at $196.2 million, although the mean value of licensing deals is above the industry average at $168 million, according to GBI Research.

One of the most lucrative recent deals, a licensing agreement between AstraZenenca and Targacept, involved a current first-in-class product, and was valued at $1.2 billion. Despite the risk that can be associated with first-in-class products, they have still been shown to be a highly desirable investment option.

Related Articles Read More >

SwRI launches Markerless Motion Capture Joint Industry Project for biomechanics research
Scientists study how to reduce airborne spread of COVID-19 virus particles
Graphene oxide membranes could reduce paper industry energy costs
Berkeley Lab team introduces new approach for whole-cell visualization, using the world’s first soft X-ray tomography (SXT) microscope

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup
Tweets by @RandDWorld

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19